Federated Hermes
TBPH icon

Federated Hermes’s Theravance Biopharma TBPH Stock Holding History

Federated Hermes’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-563
Closed -$10.5K – 2161
2025
Q4 		$10.5K Buy
563
+467
+486% +$7.75K ﹤0.01% 1832
2025
Q3 		$1.4K Buy
+96
New +$1.21K ﹤0.01% 2054
2020
Q4 		– Sell
-54
Closed -$1K – 2328
2020
Q3 		$1K Sell
54
-305,116
-100% -$5.72M ﹤0.01% 2193
2020
Q2 		$6.41M Sell
305,170
-95,804
-24% -$2.46M 0.02% 642
2020
Q1 		$9.27M Buy
400,974
+400,970
+10,024,250% +$10M 0.03% 498
2019
Q4 		$1K Sell
4
-18
-82% -$350 ﹤0.01% 2138
2019
Q3 		$1K Buy
+22
New +$444 ﹤0.01% 2132
2019
Q2 		– Sell
-46,008
Closed -$1.04M – 2216
2019
Q1 		$1.04M Hold
46,008
– – ﹤0.01% 1293
2018
Q4 		$1.18M Buy
+46,008
New +$1.24M ﹤0.01% 1235
2016
Q3 		– Sell
-334
Closed -$8K – 2166
2016
Q2 		$8K Sell
334
-705
-68% -$15.2K ﹤0.01% 1835
2016
Q1 		$20K Buy
+1,039
New +$17K ﹤0.01% 1734

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's TBPH Position: Q1 2026 in Review

Federated Hermes sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 563 shares — an estimated $10.5K sold.

Federated Hermes first reported a position in TBPH in Q1 2016 and held it in 11 quarters. The position peaked at $9.27M in Q1 2020. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Federated Hermes reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Federated Hermes sold 563 Theravance Biopharma shares in Q1 2026, an estimated $10.5K.
  • Federated Hermes first reported a position in Theravance Biopharma in Q1 2016 and held it in 11 quarters.
  • Federated Hermes's Theravance Biopharma position peaked at $9.27M in Q1 2020.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.